HMPL-306 (’306) is a novel, small-molecule, orally available, highly selective, and potent dual inhibitor of both mIDH1 and mIDH2. This is a phase 1 study of ’306 in pts with locally advanced or ...

(Sharecast News) - Hutchison China MediTech, trading as Chi-Med, has initiated a phase 1 study of 'HMPL-306', it announced on Friday, in patients with hematological malignancies in China. The AIM ...

Methods: This is a phase 1, open-label, dose escalation (Part 1) and dose expansion (Part 2) study to evaluate the safety, tolerability, pharmacokinetics ... The HMPL-306 dose will be escalated in ...